

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

Claims 1-22 (cancelled)

Claims 23-34 (withdrawn)

Claim 35 (currently amended):      A method of treating a condition characterized by abnormal activity of endothelin receptors in a subject, comprising the steps of:

    screening a library of candidate compounds by:

    contacting a sample comprising a human endothelin receptor ~~according to claim 23~~ having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: 2 with each candidate compound in the library,

    detecting binding of the candidate compound to the endothelin receptor, and

    identifying compounds which bind to the endothelin receptor;

    selecting a target compound identified from the library; and

    administering the target compound to the subject.

D<sup>4</sup> Claim 36 (currently amended):      The method of claim 35, wherein the sample comprises a cell expressing ~~the receptor of claim 23~~ a human endothelin receptor having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: 2.

Claim 37 (previously added): The method of claim 36, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.

Claims 38 and 39 (withdrawn)